Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo‐Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon‐Associated Gene Expression and Cytokines

Documenti analoghi

• Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics
  di: Grace A. Hile, et al.
  Pubblicazione: (2024)
• Subsets of Patients With Lupus Identified by Gene Expression Profiles Exhibit Differential Clinical Responsiveness to Baricitinib
  di: Prathyusha Bachali, et al.
  Pubblicazione: (2026)
• Identification of Histone Deacetylase Inhibitor Targeting Type I Interferon and B Cell Abnormalities in Systemic Lupus Erythematosus
  di: Takehiro Hirayama, et al.
  Pubblicazione: (2026)
• Trio Whole Exome Sequencing in Chinese Childhood‐Onset Lupus Reveals Novel Candidate Genes
  di: Jianyang Ma, et al.
  Pubblicazione: (2025)
• Reply
  di: Shae Chambers, et al.
  Pubblicazione: (2026)